Oral News and Research

RSS

Penn State nursing professor receives NIH grant to improve oral hygiene for dementia patients

People with dementia may soon have improved oral hygiene because of a National Institutes of Health $1.4 million, four-year grant to Rita A. Jablonski, assistant professor of nursing, Penn State.

6 May 2011

Pfizer’s Revatio receives European Commission approval for pediatric treatment of pulmonary arterial hypertension

Pfizer Inc. announced that Revatio (sildenafil citrate) has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.

5 May 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

ArQule, Inc. today announced its financial results for the first quarter of 2011.

5 May 2011

IOM study calls for increased oral health awareness in the U.S.

This is the point of a new report by the Institute of Medicine, Advancing Oral Health in America, which underscores a public health crisis that has persisted more than a decade after the U.S. Surgeon General called for aggressively reversing the "silent epidemic" of America's oral health disparity. Many of the most pernicious oral health diseases are highly preventable and treatable.

5 May 2011

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation, the most common form of cardiac arrhythmia.

5 May 2011

Humana's dental benefits coverage is now available in New York

Humana Inc. announced today that its dental benefits business, HumanaDental, is now offering a variety of plans to people in New York, including New York City, Albany and Rochester.

5 May 2011

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® from the Polish Minister of Health. This approval marks a very important milestone, namely that all nine countries in the study have now given official government approval. Five of about 48 clinical centers for this global trial will be located in Poland.

5 May 2011

Submandibular gland transfer can help prevent dry mouth in cancer patients

For patients suffering from cancer in the mouth or throat, a recent study shows that a treatment called submandibular gland transfer will assist in preventing a radiation-induced condition called xerostomia.

5 May 2011

Durata receives positive EMA Scientific Advice on dalbavancin clinical development plan

Durata Therapeutics today announced the Company has received positive Scientific Advice from the European Medicines Agency on the pivotal clinical development plan for dalbavancin, Durata's long-acting, intravenous lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.

4 May 2011

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.

4 May 2011

iOWH, Center for World Health and Medicine partner to combat childhood diarrhea

The Center for World Health and Medicine at Saint Louis University and the Institute for OneWorld Health have established a joint research agreement to develop new drugs to combat diarrhea, which is the second leading cause of death worldwide in children under age 5.

4 May 2011

Santarus' budesonide MMX Phase III data in ulcerative colitis to be presented at DDW 2011

Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.

3 May 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced that the U.S. Food and Drug Administration has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

Affinium announces AFN-1252 Phase I study results in staphylococcal infections

Affinium Pharmaceuticals announced today the results of a new multiple ascending dose Phase I study of its novel, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation.

3 May 2011

FDA approves new targeted therapy to treat men with advanced prostate cancer

The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.

3 May 2011

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.

3 May 2011

Oragenics announces availability of oral care probiotics for children and adults

Florida-based biopharmaceutical company Oragenics, Inc. has announced that its oral care probiotics for children and adults will be available in Australia and New Zealand through an exclusive agreement with Australian Pharmaceutical Industries, owner of the Priceline pharmacy retail chain, and one of the leading service providers to the pharmacy industry.

3 May 2011

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

AstraZeneca announced today that the U.S. Food and Drug Administration has approved the use of NEXIUM I.V. for Injection for children ages greater than 1 month old for the short-term treatment of gastroesophageal reflux disease with erosive esophagitis when oral therapy is not possible or appropriate.

3 May 2011

Hebei Aoxing Pharma receives Chinese patent for naloxone sublingual film

Aoxing Pharmaceutical, a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, has been granted a patent by the State Intellectual Property Office of The People's Republic of China for naloxone sublingual film.

3 May 2011

Watson launches Generess Fe low-dose oral contraceptives in the U.S.

Watson Pharmaceuticals, Inc., today announced the U.S. commercial launch of Generess Fe 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lighter, predictable periods.

2 May 2011

Oral News and Research

Penn State nursing professor receives NIH grant to improve oral hygiene for dementia patients

Pfizer’s Revatio receives European Commission approval for pediatric treatment of pulmonary arterial hypertension

ArQule reports net loss of $1,466,000 for first quarter 2011

IOM study calls for increased oral health awareness in the U.S.

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Humana's dental benefits coverage is now available in New York

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

Submandibular gland transfer can help prevent dry mouth in cancer patients

Durata receives positive EMA Scientific Advice on dalbavancin clinical development plan

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

iOWH, Center for World Health and Medicine partner to combat childhood diarrhea

Santarus' budesonide MMX Phase III data in ulcerative colitis to be presented at DDW 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Affinium announces AFN-1252 Phase I study results in staphylococcal infections

FDA approves new targeted therapy to treat men with advanced prostate cancer

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

Oragenics announces availability of oral care probiotics for children and adults

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

Hebei Aoxing Pharma receives Chinese patent for naloxone sublingual film

Watson launches Generess Fe low-dose oral contraceptives in the U.S.

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News